ADZE Biotechnology Reports US Patent Office Grants Patent Claiming Novel Recombinant Adenovirus

This Notice of Allowance for broad recombinant adenovirus claims is another important step forward for ADZE, which further strengthens and expands our intellectual property portfolio.”
— Sidney Hopps, Chief Executive Officer of ADZE
 

CORAL GABLES, FLORIDA, US, September 14, 2023 — ADZE Biotechnology Announces Notice of Allowance from US Patent and Trademark Office of Application Claiming Novel Recombinant Adenovirus.

ADZE Biotechnology (ADZE) recently announced that the USPTO issued a Notice of Allowance for US Patent Application No. 16/690,733 directed to the company’s novel adenovirus platform. The allowed patent application, entitled ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES, is part of an intellectual property portfolio directed to the novel adenovirus platform, products comprising the same and therapeutic uses in humans in the field of oncology exclusively licensed from Mayo Clinic.

Issuance of the patent will expand the scope of protection of ADZE’s intellectual property, which includes a US patent and patent applications, as well as equivalent international applications, which were filed under the Patent Cooperation Treaty, for the company’s adenovirus platform and methods of using the same, as well as pipeline technologies. The allowed application includes claims directed to recombinant adenoviruses, the species recombinant adenovirus Ad657 and embodiments which are conditionally replicating. The patent was issued 5 September 2023 with a nominal term of patent exclusivity extending to late 2041 in the US.

“With our other granted patents and patent applications that assign exclusivity for the ADZE recombinant adenovirus and platform technology, this new patent provides foundational exclusivity for our substantial product candidate pipeline,” said Sidney Hopps, Chief Executive Officer of ADZE. “This Notice of Allowance for broad recombinant adenovirus claims is another important step forward for ADZE, which further strengthens and expands our intellectual property portfolio.”

This allowance increases the depth of the ADZE IP portfolio covering innovative platforms and technologies. ADZE recognizes the significant value in its IP portfolio, and the company plans to either further develop the covered technologies or license the IP to larger healthcare organizations, both of which create significant upside value for the company.

ADZE continue to expand IP exclusivity for its platform technology, including:

1. The recombinant adenovirus as PD-1 binding compound in which the recombinant adenovirus comprises a plurality of programmed cell death protein 1 (PD-1) polypeptides on its surface and methods of using the same;
2. The recombinant adenovirus or conditionally-replicating recombinant adenovirus encoding heterologous antigens;
3. The recombinant adenovirus or conditionally-replicating recombinant adenovirus encoding targeting peptides;
4. The recombinant adenovirus or conditionally-replicating recombinant adenovirus encoding immunostimulatory ligands; and
5. The recombinant adenovirus comprising chimeric fibers.

ADZE is a biopharmaceutical company focused on novel cancer therapeutics for a broad range of cancer indications. The ADZE lead product candidate, Ad657, has potential as a multidimensional oncolytic exhibiting safe and sustained intratumoral and systemic efficacy to address a broad spectrum of malignancies and solid tumor indications. ADZE has clinical trials planned for multiple indications involving intratumoral and systemic administration.

About ADZE Biotechnology

Founded in 2019, ADZE Biotechnology is an integrated research and development company focused on improving therapeutic opportunities for multiple solid tumor malignancies for an intellectual property portfolio directed to a novel recombinant adenovirus platform, products comprising the same and therapeutic uses in humans in the field of oncology. 

Forward-Looking Statements

The statements made by ADZE Biotechnology, in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe ADZE’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of ADZE Biotechnology. Actual results could differ materially from those projected due to there being no assurance that our recombinant adenovirus candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Various other factors are detailed from time to time in ADZE’s SEC reports and filings, including our Annual Report on Form 10-K filed on …, and other reports we file with the SEC, which are available at … ADZE undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law

Sidney Hopps
Adze Biotechnology, Inc.
+1 917-743-9401
Sid@adzebiotech.com

More News from Adze Biotech